| A multicentre evaluation of the NG-test DetecTool OXA-23 for the rapid detection of OXA-23 carbapenemase directly from blood cultures A Vasilakopoulou, T Naas, C Gonzalez, J Vila, D Szabo, E Riccobono, ... JAC-Antimicrobial Resistance 6 (2), dlae029, 2024 | 2 | 2024 |
| Multidrug-resistant organism bloodstream infection and hospital acquisition among inpatients in three tertiary Greek hospitals during the COVID-19 era P Karakosta, S Vourli, E Kousouli, G Meletis, A Tychala, C Louka, ... European Journal of Clinical Microbiology & Infectious Diseases, 1-6, 2024 | 2 | 2024 |
| A multicentre evaluation of the NG-test DetecTool OXA-23 for the rapid detection of OXA-23 carbapenemase directly from blood cultures. D Szabo, A Vasilakopoulou, T Naas, C Gonzalez, J Vila Grajales, ... Journal of Antimicrobial Chemotherapy, 2024, vol. 6, num. 2, 2024 | | 2024 |
| 2076. Intestinal colonization with multidrug-resistant organisms, horizontal transmission and risk for bloodstream infection P Karakosta, G Meletis, E Kousouli, E Protonotariou, S Vourli, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 146, 2023 | | 2023 |
| 2479. Impact of the COVID-19 pandemic on the hospital acquisition of multidrug-resistant organism in two Greek hospitals P Karakosta, E Kousouli, S Vourli, PC Georgiou, V Mamali, O Zarkotou, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2097, 2023 | | 2023 |
| Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa CM Gill, DP Nicolau Journal of Antimicrobial Chemotherapy 78 (1), 252-256, 2023 | 9 | 2023 |
| Can bronchial secretion cultures identify the etiologic agent of COVID-19-associated pulmonary aspergillosis in ICU patients? Comparison with a species-specific Aspergillus PCR … M Siopi, S Antonopoulou, P Mantzana, PC Georgiou, S Vourli, ... Medical Mycology 61 (1), myac094, 2023 | 3 | 2023 |
| Assessing clinical potential of old antibiotics against severe infections by multi-drug-resistant gram-negative bacteria using in silico modelling P Paranos, S Vourli, S Pournaras, J Meletiadis Pharmaceuticals 15 (12), 1501, 2022 | 6 | 2022 |
| Women and clinical microbiology 2021 KM Papp-Wallace, SD Manning, A Craney, M Kuboniwa, S Vourli Frontiers in Cellular and Infection Microbiology 12, 999967, 2022 | | 2022 |
| Pharmacodynamics of colistin resistance in carbapenemase-producing Klebsiella pneumoniae: the double-edged sword of heteroresistance and adaptive resistance J Meletiadis, P Paranos, M Tsala, S Pournaras, S Vourli Journal of Medical Microbiology 71 (10), 001565, 2022 | 2 | 2022 |
| Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and … A Papadomanolaki, M Siopi, P Karakosta, S Vourli, S Pournaras Antibiotics 11 (7), 865, 2022 | 5 | 2022 |
| Field Evaluation of the New Rapid NG-Test® SARS-CoV-2 Ag for Diagnosis of COVID-19 in the Emergency Department of an Academic Referral Hospital K Avgoulea, MI Beredaki, S Vourli, M Siopi, N Siafakas, S Pournaras Frontiers in Public Health 10, 840984, 2022 | | 2022 |
| Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece D Petropoulou, M Siopi, S Vourli, S Pournaras Frontiers in Cellular and Infection Microbiology 11, 814530, 2022 | 31 | 2022 |
| COVID-19 and antimicrobial resistance: data from the Greek electronic system for the surveillance of antimicrobial resistance—WHONET-Greece (January 2018–March 2021) M Polemis, G Mandilara, O Pappa, A Argyropoulou, E Perivolioti, ... Life 11 (10), 996, 2021 | 49 | 2021 |
| Phenotypic/genotypic profile of OXA-10-like-harboring, carbapenem-resistant Pseudomonas aeruginosa: using validated pharmacokinetic/pharmacodynamic in vivo models to further … CM Gill, A Brink, CY Chu, J Coetzee, G Dimopoulos, C Moodley, ... Antimicrobial Agents and Chemotherapy 65 (10), 10.1128/aac. 01274-21, 2021 | 3 | 2021 |
| WGS for Bacterial Identification and Susceptibility Testing in the Clinical Lab S Vourli, F Kontos, S Pournaras Application and Integration of Omics-Powered Diagnostics in Clinical and …, 2021 | 1 | 2021 |
| Use of point-of-care molecular tests reduces hospitalization and oseltamivir administration in children presenting with influenza-like illness. PV Dimopoulou D, Vourli S, Douros K, Pournaras S J Med Virol. 93 (6), 3944-3948, 2021 | 2 | 2021 |
| Detection of KPC, NDM and VIM-Producing Organisms Directly from Rectal Swabs by a Multiplex Lateral Flow Immunoassay. PS Vasilakopoulou A, Karakosta P, Vourli S, Kalogeropoulou E Microorganisms 9 (5), 942, 2021 | 16 | 2021 |
| In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime and meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas … PS Meletiadis J, Paranos P, Georgiou PC, Vourli S, Antonopoulou S, Michelaki ... Int J Antimicrob Agents., 2021 | 22 | 2021 |
| Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital JM Elisabeth Paramythiotou, George Dimopoulos, Nikolaos Koliakos, Maria ... Infectious Diseases and Therapy, 2021 | 18 | 2021 |
